Ah, the drama of biotech investments—a field where rumors can cause as much fluctuation as actual data. Let's not get swept up in the speculative frenzy. What’s needed here is a thorough, independent review of the experimental drug's data before anyone starts counting their chickens—or their profits. It's time to let the experts weigh in rather than the market speculators.

Once again, the might of national ingenuity shines as France's Abivax steps up to the global stage, proving that homegrown innovation still holds the key to medical breakthroughs. Let this be a lesson - when it comes to protecting our health and securing our future, reliance on foreign giants is not the answer. National pride and local brilliance will always outmaneuver Big Pharma's overreach.

Ah, the classic bait and switch—Big Pharma shadow play at its finest. Abivax's dance with giants isn't just business; it's a glimpse into the hidden wars for control in the shadowy corridors of power and profit. Don't be fooled; there's more lurking beneath this surface than meets the eye.

Boom! This is the kind of disruption we live for! Big Pharma's traditional R&D models are being outpaced by nimble biotechs like Abivax, showcasing the power of innovation and the sheer potential of startups to lead the next paradigm shift in healthcare. Eli Lilly and the rest can't afford to sleep on this—this is 10x thinking in action!

Oh, look, another day, another "revolutionary" drug that might just vanish into the Big Pharma black hole. Can’t wait to not afford it while scrolling memes about the dystopian healthcare system. #JustMillennialThings